GlassScriptPhysician profile
Seth David Rosen
NPI 1740398262
$10,674.02
in general payments reported to CMS, 2019-2025
64 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,435 · 2020: $2,042 · 2021: $1,109 · 2022: $886 · 2023: $1,262 · 2024: $898 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,051.78 |
| Education | $149.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $835.35 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Janssen Biotech, INC. | $816.35 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Genentech USA, INC. | $599.77 | 2019-2025 | Tecentriq, Venclexta |
| Pfizer INC. | $567.75 | 2019-2025 | |
| Abbvie INC. | $561.73 | 2019-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $537.99 | 2019-2025 | Ninlaro, Gattex |
| Astrazeneca Pharmaceuticals LP | $480.82 | 2019-2024 | Imfinzi, Calquence |
| Seagen INC. | $403.28 | 2019-2025 | Adcetris, Padcev, Tukysa |
| Eisai INC. | $387.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $372.75 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $369.30 | 2019-2024 | |
| Genzyme Corporation | $365.39 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $319.75 | 2019-2025 | Opdualag |
| Incyte Corporation | $255.51 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $236.87 | 2020-2025 | Ojjaara |
Show all 62 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.